Skip to main content

Table 28 Risperidone for children and adolescents with avoidant/restrictive food intake disorder

From: Canadian practice guidelines for the treatment of children and adolescents with eating disorders

Certainty assessment

Impact

Certainty

Importance

№ of studies

Study design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

Weight, psychological symptoms

 1

Case Report

very serious a

not serious

not serious

not serious

none

In two cases of ARFID on dose of 1 mg daily of risperidone. Weight gain was observed to target weight over several weeks.

VERY LOW

IMPORTANT

very serious a

not serious

not serious

not serious

none

Oppositional behaviour and rigidity around eating improved.

VERY LOW

IMPORTANT

  1. Explanations
  2. atwo case reports with no control group
  3. Bibliography:
  4. Case Report - Pennell 2016 [163]